Overview

Efficacy and Safety of Telbivudine in Treatment naïve Patients With Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB)

Status:
Terminated

Trial end date:
2009-02-01

Target enrollment:

Participant gender:

Summary

To evaluate the combination of telbivudine 600 mg orally (PO) once daily and peginterferon alpha-2a 180 ug subcutaneous (sq) injection weekly for antiviral efficacy in comparison to peginterferon alpha-2a monotherapy.

Phase:

Phase 3

Details

Lead Sponsor:

Novartis

Treatments:

Interferon-alpha
Peginterferon alfa-2a
Telbivudine